Logo1.png

In recent years significant advances have been made in understanding CNS pathogenesis with the development of molecular technologies for the diagnosis and monitoring of disease, the introduction of effective treatment therapies and, in some cases, the development of vaccines (e.g. Japanese encephalitis & rabies). The range of QCMD EQA schemes within this area focus on pathogens known to play a significant clinical role in CNS infection. The general aim of this group of EQA schemes is to assess the laboratories’ ability in the detection and determination of the selected pathogen.

❮ BACK TO QCMD MAIN